Mood, depression, and reproductive hormones in the menopausal transition
Section snippets
What is the evidence of an association between the menopausal transition and depression?
The majority of women do not develop depression during the menopausal transition; therefore, the perimenopause is not uniformly associated with changes in a woman’s mood.11, 12, 14, 15, 16, 17 In fact, epidemiologic studies examining sex- and age-related differences in the 6-month to 1-year prevalence of major depression reported no increased prevalence of major depression in women at midlife (age range, approximately 45 to 55 years).1 Nonetheless, although the postmenopause is not associated
What factors influence the risk for depression during the menopausal transition?
As described in the previous section, several epidemiologic studies have surveyed the presence of depressive symptoms in women at midlife and identified rates of depressive symptoms ranging from 8% to 40%.18, 28 However, the samples in these studies consisted of women at midlife who were in different phases of reproductive aging, and depressive symptoms often were assessed independently of the presence of clinically meaningful depressive syndromes. These findings, therefore, are not directly
What is the evidence that age-related alterations in ovarian hormone secretion contribute to the development of depression in some middle-aged women?
There have been no differences in plasma levels of reproductive or adrenal (i.e., dehydroepiandrosterone) hormones identified consistently in women with perimenopausal depression compared with control subjects. Thus, depression during the perimenopause is not distinguished by abnormally low plasma levels of estrogens or androgens.30 However, 3 double-blind placebo-controlled trials using similar methodologies and identical preparations of estrogen (i.e., 17β-estradiol), have examined the
Summary
Recent evidence from prospective epidemiologic studies suggests that for some women the endocrine events (e.g., alterations in gonadotropin secretion, decreased estradiol secretion) during the perimenopause are associated with the onset of depression. Additionally, although perimenopausal depression is not characterized by abnormalities of basal ovarian hormone secretion, 2 randomized controlled trials reported therapeutic benefits of estradiol in perimenopausal depressed individuals. The
Acknowledgment
The author acknowledges the thoughtful contributions to the manuscript provided by Dr. David R. Rubinow.
References (36)
- et al.
Prevalence, correlates, and course of minor depression and major depression in the national comorbidity survey
J Affect Disord
(1997) - et al.
Major depressive disorder
Neuron
(2000) - et al.
The Manitoba projecta re-examination of the link between menopause and depression
Maturitas
(1992) - et al.
Change in psychological and vasomotor symptom reporting during the menopause
Soc Sci Med
(2002) - et al.
A longitudinal analysis of the association between menopause and depressionresults from the Massachusetts Women’s Health Study
Ann Epidemiol
(1994) The South-East England longitudinal study of the climacteric and postmenopause
Maturitas
(1992)- et al.
Is there a menopausal syndrome? menopausal status and symptoms across racial/ethnic groups
Soc Sci Med
(2001) - et al.
Basal plasma hormone levels in depressed perimenopausal women
Psychoneuroendocrinology
(2002) - et al.
Estrogen replacement in perimenopause-related depressiona preliminary report
Am J Obstet Gynecol
(2000) - et al.
Lack of efficacy of estradiol for depression in postmenopausal womena randomized, controlled trial
Biol Psychiatry
(2004)
A meta-analysis of the effect of hormone replacement therapy upon depressed mood
Psychoneuroendocrinology
Effect of oestrogen and testosterone implants on psychological disorders in the climacteric
Lancet
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United Statesresults from the National Comorbidity Survey
Arch Gen Psychiatry
The global burden of disease, 1990–2020
Nature Med
Subsyndromal symptomatic depressiona new mood disorder?
J Clin Psychiatry
Duration of major depressive episodes in the general populationresults from the Netherlands Mental Health Survey and Incidence Study (NEMESIS)
Br J Psychiatry
Defining the menopausal transition
Am J Med
Cited by (80)
The role of estradiol fluctuation in the pathophysiology of perimenopausal depression: A hypothesis paper
2021, PsychoneuroendocrinologyCitation Excerpt :We furthermore provide a brief overview of the neuroendocrine mechanisms potentially mediating the effect of E2 changes on mood, and finish with a discussion of proposed clinical implications and future research. E2 withdrawal has long been hypothesised to be involved in the development of perimenopausal depressive symptoms (Schmidt, 2005). The fact that depression risk declines considerably in the late postmenopausal phase suggests that low but stable E2 levels are not problematic – rather, research evidence suggests that the decline from reproductive levels of E2 to postmenopausal levels are most likely to trigger depressive mood.
Brain estrogen alters the effects of the antidepressant sertraline in middle-aged female and male mice
2020, Molecular and Cellular EndocrinologyReducing depression during the menopausal transition with health coaching: Results from the healthy menopausal transition randomised controlled trial
2016, MaturitasCitation Excerpt :The menopausal transition (MT) is often described as a period of increased vulnerability to depressive symptoms [1,2], with most longitudinal studies demonstrating an increase in the prevalence of depression during this period [3,4]. Changes in gonadotrophins and/or sex steroids [5,6], history of past depression, vasomotor symptoms, weight gain, physical inactivity, poor social support, changing psychosocial roles, chronic diseases, and perceived loss of control have all been implicated as risk factors [7–11]. Despite growing recognition that women in the MT may be more susceptible to depression, no systematic attempts have been made to prevent this happening.
Sex hormones and adult hippocampal neurogenesis: Regulation, implications, and potential mechanisms
2016, Frontiers in NeuroendocrinologyPuberty and perimenopause: Reproductive transitions and their implications for women's health
2015, Social Science and MedicineCitation Excerpt :Women may also be more susceptible to high anxiety during perimenopause: at least one study has found that odds of high anxiety peak during late perimenopause—although not among women with high anxiety upon entering the menopausal transition (Bromberger et al., 2013). Higher prevalence of mood disorders and symptoms during puberty and perimenopause is usually tied to fluctuations in sex hormones (Angold et al., 1999; Freeman et al., 2006, 2004; Goodyer et al., 2001; Goodyer et al., 2000; Halbreich and Kahn, 2001; Nolen-Hoeksema, 2001; Schmidt, 2005; Steiner et al., 2003). Most theories propose one of two types of models to explain the developmental rise of mood disorders during reproductive transitions: an indirect model whereby hormones affect some general physiological system such as psychological arousal, neurotransmitters, or reactivity to stressors that increases risk for mood disorders; or an interaction model in which social context or environments, in addition to hormones, contribute to risk (Hyde et al., 2008).
Women's Health, Neurology of
2014, Encyclopedia of the Neurological Sciences
The opinions offered at the National Institutes of Health (NIH) State-of-the-Science Conference on Management of Menopause-Related Symptoms and published herein are not necessarily those of the National Institute on Aging (NIA) and the Office of Medical Applications of Research (OMAR) or any of the cosponsoring institutes, offices, or centers of the NIH. Although the NIA and OMAR organized this meeting, this article is not intended as a statement of Federal guidelines or policy.
Publication of the online supplement was made possible by funding from the NIA and the National Center for Complementary and Alternative Medicine of the NIH, US Department of Health & Human Services.